Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Leukemia & Lymphoma
Katherine L B Borden, Biljana Culjkovic-Kraljacic

Abstract

Ribavirin was discovered nearly 40 years ago as a broad-spectrum antiviral drug. Recent data suggest that ribavirin may also be an effective cancer therapy. In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. In a phase II clinical trial, ribavirin treatment led to substantial clinical benefit in patients with poor-prognosis acute myeloid leukemia (AML). Here molecular targeting of eIF4E correlated with clinical response. Ribavirin also targets a key enzyme in the guanosine biosynthetic pathway, inosine monophosphate dehydrogenase (IMPDH), and also modulates immunity. Parallels with known antiviral mechanisms could be informative; however, after 40 years, these are not entirely clear. The antiviral effects of ribavirin appear cell-type specific. This variation likely arises for many reasons, including cell specific variations in ribavirin metabolism as well as virus specific factors. Thus, it seems that the mechanisms for ribavirin action in cancer therapy may also vary in terms of the cancer/tissu...Continue Reading

References

Jul 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·R C WillisJ E Seegmiller
Aug 13, 1979·Biochemical and Biophysical Research Communications·B B GoswamiR A Smith
Mar 4, 1977·Annals of the New York Academy of Sciences·J P MillerJ Roboz
Jan 1, 1990·The International Journal of Biochemistry·T Page, J D Connor
May 31, 1988·Biochemical and Biophysical Research Communications·Y NatsumedaG Weber
Jul 1, 1986·Antimicrobial Agents and Chemotherapy·D F Smee, T R Matthews
Apr 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·D G StreeterL N Simon
Nov 9, 1994·Molecular and Cellular Biochemistry·T W Traut
Apr 30, 1998·Current Opinion in Cell Biology·N Sonenberg, A C Gingras
May 30, 1998·Annals of Surgery·B D LiA De Benedetti
Jun 2, 1998·Annals of Surgical Oncology·D L SorrellsB D Li
Mar 17, 1999·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·D L SorrellsB D Li
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C O NathanJ Glass
Jul 11, 2000·The Journal of Biological Chemistry·T von Der HaarJ E McCarthy
Apr 20, 2002·Differentiation; Research in Biological Diversity·Stephen Strudwick, Katherine L B Borden
May 1, 2002·Annals of Surgery·Benjamin D L LiArrigo DeBenedetti
Aug 21, 2002·Thyroid : Official Journal of the American Thyroid Association·S WangA Khan
Nov 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Alex KentsisKatherine L B Borden
Nov 21, 2002·The Journal of Biological Chemistry·Shunan LiVitaly A Polunovsky
Dec 3, 2002·Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progrès Des Recherches Pharmaceutiques·Zhi Hong, Craig E Cameron
Mar 4, 2003·Nature Reviews. Cancer·Davide Ruggero, Pier Paolo Pandolfi
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Chin-Chung LinLi-Tain Yeh
Aug 28, 2003·American Journal of Respiratory and Critical Care Medicine·Dian-Jung ChiangBor-Luen Chiang
Feb 26, 2004·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Milton W TaylorHoward J Edenberg
Mar 19, 2004·Nature·Hans-Guido WendelScott W Lowe

❮ Previous
Next ❯

Citations

Apr 16, 2013·Trends in Cell Biology·Biljana Culjkovic-Kraljacic, Katherine L B Borden
Apr 16, 2013·Trends in Cell Biology·Barbara J Natalizio, Susan R Wente
Mar 12, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Martin Carroll, Katherine L B Borden
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Filippa PetterssonWilson H Miller
Nov 21, 2012·Infectious Agents and Cancer·Kenneth AlibekBolat Sultankulov
Aug 31, 2012·BMC Systems Biology·Giuseppe FacchettiClaudio Altafini
Jun 2, 2012·World Journal of Gastroenterology : WJG·Xiao-Lin WangXiao-Feng Su
Oct 3, 2014·Molecular Biology of the Cell·Leon Juvenal HajingaboJean-Claude Twizere
Dec 18, 2012·Journal of Cancer Research and Clinical Oncology·Yasuhiro SaitoKatsuhiro Uzawa
Sep 4, 2014·Genes·Amandine Bonnet, Benoit Palancade
Mar 5, 2015·Oncology Reports·Erick De la Cruz-HernandezAlfonso Dueñas-Gonzalez
Jan 19, 2016·Expert Reviews in Molecular Medicine·Chunwan LuYafei Cai
Jan 7, 2015·The Journal of Investigative Dermatology·Shahram KhosraviChristopher J Ong
Jul 29, 2011·Wiley Interdisciplinary Reviews. RNA·Nadeem Siddiqui, Katherine L B Borden
Aug 12, 2015·Journal of Experimental & Clinical Cancer Research : CR·David Díaz-CarballoDirk Strumberg
Dec 17, 2014·Immunological Reviews·Michael J Osborne, Katherine L B Borden
Dec 11, 2014·European Journal of Medicinal Chemistry·Joanna ZeidlerTomasz Ostrowski
Aug 21, 2012·Cell Reports·Biljana Culjkovic-KraljacicKatherine L B Borden
Apr 16, 2013·Biochemical and Biophysical Research Communications·Laurent VolponKatherine L B Borden
Jul 6, 2016·Pharmacological Reports : PR·Sapna SharmaMilee Agarwal
Nov 8, 2016·Experimental Cell Research·Andjelka M IsakovicAleksandra Isakovic
Jul 30, 2015·PloS One·Jeffrey M B MusserIan R Tizard
Jan 27, 2017·Journal of the National Cancer Institute·Wanpei CaiAlan Prem Kumar
Jan 1, 2012·Cancers·Sarit AssoulineKatherine L B Borden
Mar 3, 2011·Nature Reviews. Clinical Oncology·Sarah P Blagden, Anne E Willis
Jun 25, 2019·Current Hematologic Malignancy Reports·Ipsita PalChangchun Deng
Jan 15, 2019·Current Protein & Peptide Science·Laurent VolponKatherine L B Borden
Nov 5, 2014·Oncology Letters·Akiyoshi OginoYoichi Katayama
Sep 14, 2019·Cancers·Rand NaffoujeAtsuo T Sasaki
May 16, 2017·Beilstein Journal of Organic Chemistry·Fanny CossonNadège Lubin-Germain
Mar 5, 2020·Nucleosides, Nucleotides & Nucleic Acids·Alexander N PrutkovYulia V Berezovskaya
Mar 1, 2018·Oncotarget·Joshua CasaosNicolas Skuli
Jun 21, 2020·Journal of Clinical Medicine·Debora ValliMyriam Alcalay
Nov 28, 2018·Oncogene·Karen A UrtishakCarolyn A Felix
Mar 28, 2017·Infectious Agents and Cancer·Madina ShaimerdenovaDana Akilbekova
Aug 11, 2018·Veterinary Research Communications·Qiu-Yan ChangXiao-Xia Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.